Honoring Breast Cancer Awareness Month: Local researchers driving global impact
Each October, Breast Cancer Awareness Month offers a moment to reflect on progress and recommit to advancing cancer research and care. Here in the Pacific Northwest, we are fortunate to live in a region that is driving and defining the future of cancer innovation. The Kuni Foundation is honored to partner with world-class cancer researchers in Washington and Oregon, supporting
Honoring Native American Heritage Month: Transforming cancer care across the Northwest
The Pacific Northwest is a global leader in cancer research, home to innovative science and transformational studies across our region. Yet not all communities benefit equally from these advances. Native American and Alaska Native communities throughout Washington and Oregon face higher rates of cancer diagnoses than the general population—and, in Washington, a higher rate of death from cancer. These disparities are compounded
Kuni Foundation grants more than $4.5 million to expand and sustain inclusive housing, advance impactful cancer and disability research
Vancouver, Wash. — Dec. 16, 2025 — Amid historic federal funding cuts and ongoing uncertainty, the Kuni Foundation has awarded more than $4.5 million to community partners across Washington and Oregon. This represents a 42% increase in funding compared to the Foundation’s fall 2024 grant cycle. “We’re energized by the depth and breadth of the projects we’re able to help
Stepping Stones to Stability: Addressing Intersection of Homelessness and Intellectual Challenges
Over the years of working with homeless youth in the Seattle area, Ryther has recognized a pattern: young adults experiencing intellectual and developmental disabilities (IDD) who become homeless have the greatest difficulty in accessing housing and other resources. They are often kicked out of shelters and housing programs for “inappropriate behavior,” and frequently don’t have access to needed psychological testing
PDX Pharmaceuticals Secures Additional Investment from the Kuni Foundation to Advance New Cancer-Fighting Precision Therapies
Portland, Oregon — PDX Pharmaceuticals, a privately held company developing first-in-class nanotechnology-based therapies for treating cancer, received a second round of Series A funding in the amount of $2 million from the Kuni Foundation. PDX Pharmaceuticals, a startup that originated in the Biomedical Engineering Department of Oregon Health & Science University (OHSU) in collaboration with the Knight Cancer Institute, has developed a new class of therapeutics based on co-delivery of siRNA and drugs on immuno-nanoparticles. The
